Latest Intellectual Property News

Page 1 of 89
PlaySide Studios has emerged from a difficult year with a sharp EBITDA recovery, more than 1 million MOUSE sales and A$7.3 million of new FY27 external-project contracts. Its next test is converting that momentum into a successful Game of Thrones launch and more durable cash flow.
Victor Sage
Victor Sage
19 Nov 2026
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
Metallium has commissioned an upgraded Flash Joule Heating reactor in Texas for its first commercial technology-services program beyond metals recovery. The early-stage MXene campaign is funded by Environmental Clean Technologies and could generate up to US$1.4 million over 12 months while Metallium retains its reactor and process intellectual property.
Victor Sage
Victor Sage
18 Nov 2026
Infratil lifted FY27 operating EBITDAF guidance after a 28% first-half increase, led by data centres, renewables and One NZ. But the growth came with a NZ$247.8 million loss attributable to shareholders, a NZ$256 million incentive-fee provision and a sharp increase in capital spending.
Victor Sage
Victor Sage
18 Nov 2026
IPH has opened FY27 with an 8.4% revenue decline and a 13.4% fall in underlying EBITDA, with currency movements only partly explaining the weakness. New CEO Tony O’Malley says restoring organic growth in Australia and New Zealand is now a clear priority.
Victor Sage
Victor Sage
17 Nov 2026
Corazon Mining is evaluating a modular 600,000-tonne-per-year gold plant at Chalice under a build-own-operate model that could limit its upfront processing capital. The non-binding plan targets a BOO proposal by April 2027 and potential commissioning in Q1 2028, while toll treatment remains available as an interim option.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
HyTerra has secured an 18-month exclusive MOU to evaluate a 256 km² natural hydrogen opportunity in Ras Al Khaimah, UAE. The arrangement expands its Semail Ophiolite exposure, but does not yet provide exploration tenure, require drilling or guarantee a commercial agreement.
Maxwell Dee
Maxwell Dee
12 Nov 2026
COSOL expects H1 FY27 revenue to remain broadly flat while statutory EBITDA improves, as a new 10-year US transit contract gives its turnaround strategy a concrete test. The ASX-listed technology group is also targeting dividend resumption after H1 FY28.
Victor Sage
Victor Sage
12 Nov 2026
Anagenics will acquire Australian skincare brand Bio-First for $50,000 in shares, adding existing formulations, digital assets and a database of more than 25,000 email contacts. The company plans to relaunch the brand through BLC Cosmetics’ established ecommerce and professional beauty channels.
Victor Sage
Victor Sage
11 Nov 2026
Capability X is seeking A$12 million through a proposed ASX listing to expand its edge AI, remote operations and industrial safety business. The opportunity comes with a sharp financial caveat: FY2026 revenue fell to A$1.06 million, the company lost A$3.17 million and its auditor flagged material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
10 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026

Browse the archive

Full archive